Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

234192 Anti-Collagen Type VII Rabbit pAb

234192
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

Species ReactivityHostAntibody Type
H, MarmosetRbPolyclonal Antibody

Products

RéférenceConditionnement Qté
234192-500UL Ampoule plast. 500 ul
Description
OverviewRecognizes type VII collagen. Does not cross-react with fibronectin or type I, type II, type III, type IV, or type VI collagen.
Catalogue Number234192
Brand Family Calbiochem®
References
ReferencesChen, M., et al. 1997. Invest. Dermatol. 108, 68.
Hashimoto, T., et al. 1996. Br. J. Dermatol. 134, 336.
Yasaka, N., et al. 1994. J. Dermatol. Sci. 7, 136.
Product Information
FormLiquid
Preservative≤0.1% sodium azide
Quality LevelMQ100
Applications
Key Applications Frozen Sections
Immunoblotting (Western Blotting)
Immunofluorescence
Immunoprecipitation
Application NotesFrozen Sections (1:20-1:60, see comments)
Immunoblotting (1:500-1:2000)
Immunofluorescence (1:200)
Immunoprecipitation (1:40-1:100)
Application CommentsDoes not cross-react with fibronectin or other collagen types I, II, III, IV, or VI. For frozen sections, enzymatic or heat (41°C) pretreatment is recommended to unwind the triple helical structure. Antibody should be titrated for optimal results in individual systems.

This protocol is provided only as a general guide. Researchers should standardize this assay for their own specific needs and should consult published literature.

Immunohistochemistry Protocol

Introduction


Staining of cryosections using anti-collagen antibodies requires either heat and/or enzymatic treatment in order to unwind the triple helical structure of collagen. An initial heat treatment aids in unwinding the collagen, while maintaining the antigen structure. Subsequent enzymatic treatment with hyaluronidase facilitates the removal of macromolecules that further hinder recognition by the antibody. In some cases it is also necessary to perform a second enzymatic digestion using chondroitinase ABC.

Protocol

Reagents and Equipment:

• Cryostat sections of desired tissue: cut into 5 mm sections and place on clean glass slides treated with poly-L-lysine
• PBS (phosphate buffered saline): dissolve 8 g NaCl, 200 mg KCl, 1.44 g Na2HPO4, and 240 mg KH2PO4 in 800 ml dH2O; adjust the pH to 7.4 with HCl; add dH2O to 1 L
• PBS/BSA (phosphate buffered saline/bovine serum albumin): 0.5% BSA prepared in PBS
• Testicular hyaluronidase: 2 mg/ml in cold PBS
• Chondroitinase ABC: 2 mg/ml in PBS
• Normal sheep serum
• Primary antibody: Anti-Collagen, Type VII Rabbit pAb (Cat. No. 234192); diluted as recommended
• Secondary antibody: goat anti-rabbit IgG, fluorescein conjugated
p-Phenylenediamine: 0.1% in glycerin:PBS (9:1)
• Staining chamber
• Wet chamber for incubations: chamber in which a small amount of PBS or dH2O is added to maintain a humid environment; slides should not be submerged

Protocol:

• Prepare 5 µm cryostat tissue sections from the tissue of choice and place on clean glass slides that have been treated with poly-L-lysine.
• Incubate the tissue sections in a staining chamber with 0.5% BSA/PBS for 5-10 min at 41°-43°C. This serves to block the sections and unwind the helical structure.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• Treat the sections with 10 µl of hyaluronidase stock (2 mg/ml) by applying the enzyme directly to the sections on the slide. If 10 µl does not completely cover the section, increase the volume of enzyme until the section is completely covered. Incubate in a wet chamber at room temperature for 30 min. Stop the reaction by treatment of the sections with 25-50 µl of normal sheep serum.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• If desired, a second enzymatic treatment can be carried out by treating the sections with 10 µl of chondroitinase ABC (2 mg/ml); apply directly to the sections as above. If 10 µl does not completely cover the section, increase the volume of enzyme until the section is completely covered. Incubate in a wet chamber at room temperature for 30 min. Stop the reaction by treatment of the sections with 25-50 µl of normal sheep serum.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• Apply 5-10 µl of primary antibody (diluted to the desired concentration) to the section and incubate in a wet chamber at 37°C for 45 min.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• Apply 5-10 µl of secondary antibody (diluted to the desired concentration) to the section and incubate in a wet chamber at 37°C for 1 h. Protect from light during the incubation.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS in a staining chamber. Carefully remove excess fluid, but do not allow the slides to completely dry, as the secondary antibody may form crystals.
• Place 1 drop of 0.1% p-phenylenediamine on the section and mount under a coverslip. The slides can be stored at 4°C up to 2 days.
• Fixation:
The best results have been obtained on cryosections without fixation. The risk of collagen loss is relatively low, as its solubility in neutral buffer is negligible. However, other antigens may diffuse into the incubation medium and settle along adjacent tissue structures or form diffusion artifacts. If fixation is necessary, dehydration with ethanol or acetone at -20°C for 5-10 min is recommended. Fixation should take place following enzymatic treatment (step 5). Aldehyde (formaldehyde or glutaraldehyde) fixation is NOT recommended. If aldehyde fixation cannot be avoided, do not exceed 2% of the fixative (less than 1% is recommended).

Notes:

• It may not be necessary to treat the sections with both heat and hyaluronidase and/or chondroitinase ABC. It is recommended that heat treatment be used initially and, if further epitope exposure is necessary, then treat with hyaluronidase. Chondroitinase ABC treatment is usually not necessary.
• If hyaluronidase and chondroitinase ABC are both desired, it is recommended that the digestions be carried out separately.
Biological Information
Immunogenpurified, human placenta collagen type VII
ImmunogenHuman
HostRabbit
IsotypeIgG
Species Reactivity
  • Human
  • Marmoset
Antibody TypePolyclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
234192-500UL 04055977200102

Documentation

Anti-Collagen Type VII Rabbit pAb FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

Anti-Collagen Type VII Rabbit pAb Certificats d'analyse

TitreNuméro de lot
234192

Références bibliographiques

Aperçu de la référence bibliographique
Chen, M., et al. 1997. Invest. Dermatol. 108, 68.
Hashimoto, T., et al. 1996. Br. J. Dermatol. 134, 336.
Yasaka, N., et al. 1994. J. Dermatol. Sci. 7, 136.
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision26-July-2007 RFH
ApplicationFrozen Sections (1:20-1:60, see comments)
Immunoblotting (1:500-1:2000)
Immunofluorescence (1:200)
Immunoprecipitation (1:40-1:100)
DescriptionRabbit polyclonal antibody supplied as undiluted serum. Recognizes type VII collagen.
BackgroundCollagens are major fibrous structural elements of cartilage, tendon, bone, skin, lung, and blood vessels. Type VII collagen exists as a dimer of two triple helical coils, each of which is composed of three a1 (VII) subunits. Type VII collagen forms a major portion of anchoring fibrils that provide for the structural stability of subbasal lamina. Type VII collagen is associated with type IV collagen in anchoring plaques.
HostRabbit
Immunogen speciesHuman
Immunogenpurified, human placenta collagen type VII
IsotypeIgG
Specieshuman, marmoset
FormLiquid
Preservative≤0.1% sodium azide
CommentsDoes not cross-react with fibronectin or other collagen types I, II, III, IV, or VI. For frozen sections, enzymatic or heat (41°C) pretreatment is recommended to unwind the triple helical structure. Antibody should be titrated for optimal results in individual systems.

This protocol is provided only as a general guide. Researchers should standardize this assay for their own specific needs and should consult published literature.

Immunohistochemistry Protocol

Introduction


Staining of cryosections using anti-collagen antibodies requires either heat and/or enzymatic treatment in order to unwind the triple helical structure of collagen. An initial heat treatment aids in unwinding the collagen, while maintaining the antigen structure. Subsequent enzymatic treatment with hyaluronidase facilitates the removal of macromolecules that further hinder recognition by the antibody. In some cases it is also necessary to perform a second enzymatic digestion using chondroitinase ABC.

Protocol

Reagents and Equipment:

• Cryostat sections of desired tissue: cut into 5 mm sections and place on clean glass slides treated with poly-L-lysine
• PBS (phosphate buffered saline): dissolve 8 g NaCl, 200 mg KCl, 1.44 g Na2HPO4, and 240 mg KH2PO4 in 800 ml dH2O; adjust the pH to 7.4 with HCl; add dH2O to 1 L
• PBS/BSA (phosphate buffered saline/bovine serum albumin): 0.5% BSA prepared in PBS
• Testicular hyaluronidase: 2 mg/ml in cold PBS
• Chondroitinase ABC: 2 mg/ml in PBS
• Normal sheep serum
• Primary antibody: Anti-Collagen, Type VII Rabbit pAb (Cat. No. 234192); diluted as recommended
• Secondary antibody: goat anti-rabbit IgG, fluorescein conjugated
p-Phenylenediamine: 0.1% in glycerin:PBS (9:1)
• Staining chamber
• Wet chamber for incubations: chamber in which a small amount of PBS or dH2O is added to maintain a humid environment; slides should not be submerged

Protocol:

• Prepare 5 µm cryostat tissue sections from the tissue of choice and place on clean glass slides that have been treated with poly-L-lysine.
• Incubate the tissue sections in a staining chamber with 0.5% BSA/PBS for 5-10 min at 41°-43°C. This serves to block the sections and unwind the helical structure.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• Treat the sections with 10 µl of hyaluronidase stock (2 mg/ml) by applying the enzyme directly to the sections on the slide. If 10 µl does not completely cover the section, increase the volume of enzyme until the section is completely covered. Incubate in a wet chamber at room temperature for 30 min. Stop the reaction by treatment of the sections with 25-50 µl of normal sheep serum.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• If desired, a second enzymatic treatment can be carried out by treating the sections with 10 µl of chondroitinase ABC (2 mg/ml); apply directly to the sections as above. If 10 µl does not completely cover the section, increase the volume of enzyme until the section is completely covered. Incubate in a wet chamber at room temperature for 30 min. Stop the reaction by treatment of the sections with 25-50 µl of normal sheep serum.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• Apply 5-10 µl of primary antibody (diluted to the desired concentration) to the section and incubate in a wet chamber at 37°C for 45 min.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS. Carefully remove excess fluid and air-dry the slides.
• Apply 5-10 µl of secondary antibody (diluted to the desired concentration) to the section and incubate in a wet chamber at 37°C for 1 h. Protect from light during the incubation.
• Carefully rinse by briefly submerging in PBS.
• Wash 2 x 10 min in PBS in a staining chamber. Carefully remove excess fluid, but do not allow the slides to completely dry, as the secondary antibody may form crystals.
• Place 1 drop of 0.1% p-phenylenediamine on the section and mount under a coverslip. The slides can be stored at 4°C up to 2 days.
• Fixation:
The best results have been obtained on cryosections without fixation. The risk of collagen loss is relatively low, as its solubility in neutral buffer is negligible. However, other antigens may diffuse into the incubation medium and settle along adjacent tissue structures or form diffusion artifacts. If fixation is necessary, dehydration with ethanol or acetone at -20°C for 5-10 min is recommended. Fixation should take place following enzymatic treatment (step 5). Aldehyde (formaldehyde or glutaraldehyde) fixation is NOT recommended. If aldehyde fixation cannot be avoided, do not exceed 2% of the fixative (less than 1% is recommended).

Notes:

• It may not be necessary to treat the sections with both heat and hyaluronidase and/or chondroitinase ABC. It is recommended that heat treatment be used initially and, if further epitope exposure is necessary, then treat with hyaluronidase. Chondroitinase ABC treatment is usually not necessary.
• If hyaluronidase and chondroitinase ABC are both desired, it is recommended that the digestions be carried out separately.
Storage Avoid freeze/thaw
≤ -70°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Toxicity Standard Handling
ReferencesChen, M., et al. 1997. Invest. Dermatol. 108, 68.
Hashimoto, T., et al. 1996. Br. J. Dermatol. 134, 336.
Yasaka, N., et al. 1994. J. Dermatol. Sci. 7, 136.